NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
-- Strong financial position; ending the quarter with $481.1 million in cash --
- Driven by strong patient and physician interest globally, NewAmsterdam extended enrollment to the end of April and randomized over 9,500 patients.
- In January 2024, NewAmsterdam appointed William H. Lewis, J.D., M.B.A as Chair of its Board of Directors.
- NewAmsterdam currently expects to achieve the following upcoming milestones:
Announce topline data from the Phase 3 BROOKLYN trial for obicetrapib monotherapy in the third quarter of 2024. - Revenue: NewAmsterdam recognized $1.4 million in revenue for the quarter ended March 31, 2024, compared to $8.6 million in the same period in 2023.